Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 565 • 2018 ACR/ARHP Annual Meeting
Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
Thierry Dervieux¹, Marie Grosjean², Chuang Jiang^3,4, Kelley Brady¹, Kjeld Schmiegelow², Joel Kremer⁵ and Jun Yang⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²University Hospital Rigshospitalet, Copenhagen, Denmark, ³Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China, ⁴Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate (MTX) is anti-folate activated to MTX polyglutamates (MTXPGs). MTX metabolism includes multiple enzyme-mediated reactions and genetic polymorphisms in these genes are linked to…
Abstract Number: 571 • 2018 ACR/ARHP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab
Aaron Broadwell¹, Vance Bray², Douglas Conaway³, Joy Schechtman⁴, Alan J. Kivitz⁵, Dennis Parenti⁶, Shawn Black⁶, Stephen Xu⁷, Wayne Langholff⁷ and Shelly Kafka⁶, ¹Rheumatology Osteoporosis Specialists, Shreveport, LA, ²Denver Arthritis Clinic, Denver, CO, ³Carolina Health Specialists, Myrtle Beach, SC, ⁴Sun Valley Arthritis Center, Peoria, AZ, ⁵Altoona Arthritis & Osteoporosis Center, Altoona, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
Abstract Number: 608 • 2018 ACR/ARHP Annual Meeting
Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission
Takeshi Suzuki, Takayasu Ando, Shoshi Shinagawa, Machiko Mizushima, Tomohiko Shibata and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Recently, it is recommended that tapering csDMARDs could be considered If a patient is in persistent remission. However, the methods of tapering csDMARDs including…
Abstract Number: 616 • 2018 ACR/ARHP Annual Meeting
Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX
Pamela B. Rosenthal¹, Jeffrey S. Berger² and Bruce N. Cronstein¹, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Low dose weekly MTX remains the anchor drug for treatment of Rheumatoid Arthritis. The principal mechanism by which MTX suppresses inflammation in Rheumatoid Arthritis…
Abstract Number: 539 • 2017 ACR/ARHP Annual Meeting
Comparison of Oral Versus Parenteral Methotrexate in Rheumatoid Arthritis: A Meta-Analysis
Sahar Janjua¹, Andreea Bujor¹, Michael P. LaValley², Josefina Duran³, Jürgen Braun⁴ and David T. Felson⁵, ¹Department of Rheumatology, Boston Medical Center, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Pontificia Universidad Católica de Chile, Santiago, Chile, ⁴Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Methotrexate (MTX) is the mainstay first-line therapy for rheumatoid arthritis (RA), and it can be given orally or parenterally. Bioavailability of oral MTX may…
Abstract Number: 1438 • 2017 ACR/ARHP Annual Meeting
Is It Necessary to Weight By Weight the Dosage of MTX in RA Patients? Results from Obsevational Analysis of Baseline Data of a Phase III Trial
Alain Saraux¹, Christophe Hudry², Elena Zinovieva³ and Hélène Herman-Demars³, ¹Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ²AP-HP Hôpital Cochin, Paris, France, ³Medical Department Nordic Pharma, Paris, France
Background/Purpose: In inflammatory rheumatic diseases, pharmacokinetics of MTX may be modified by patients’ weight [1]. The rheumatologists are though reluctant to prescribe a high dosage…
Abstract Number: 1738 • 2017 ACR/ARHP Annual Meeting
The Pattern of Proinflamatory Cytokine Expression By CD4+ T Lymphocytes Segregates the Clinical Response to Methotrexate in Recently Diagnosed Rheumatoid Arthritis Patients
Jorge Monserrat Sanz¹, Ana Maria Gómez Lahoz², Cristina Bohórquez Heras³, Maria Dolores Sosa Reina², Atusa Movasat³, Ana Pérez Gómez³, Lucía Ruiz Gutiérrez³, Ana Sánchez Atrio³, Eduardo Cuende Quintana³, Maria José León³, David Diaz², Fernando Albarrán Hernández³ and Melchor Alvarez-Mon^2,3, ¹Laboratory of Inmune System Diseases, Deparment of Medicine and Medical Specialties. IRYCIS. University of Alcalá. Madrid. Spain, Alcalá de Henares. Madrid, Spain, ²Laboratory of Inmune System Diseases, Deparment of Medicine and Medical Specialties. IRYCIS. University of Alcalá. Madrid. Spain, Alcalá de Henares, Madrid, Spain, ³University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain
Background/Purpose: Mechanisms regulating the autoimmune response in rheumatoid arthritis (RA) are not well understood. However, it is known that T CD4+ lymphocytes play a pivotal…
Abstract Number: 2380 • 2017 ACR/ARHP Annual Meeting
The Use of Fibroscan in Detecting Early Liver Fibrosis in RA Patients on Long Term MTX with Normal Liver Enzymes
Malack Alachkar¹, T Mathialahan², Sandra Walsh² and Vun Lim³, ¹Rheumatology, The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ²Gastroenterology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom, ³Rheumatology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom
Background/Purpose: FibroScan (FS) is a non-invasive investigation that allows assessment of possible liver fibrosis by measuring liver stiffness. There are studies which confirm that MTX-related…
Abstract Number: 2479 • 2017 ACR/ARHP Annual Meeting
Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese¹, Erin K. Mangan², Toshio Kimura², Melitza Iglesias-Rodriguez³ and Tom W.J. Huizinga⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Cambridge, MA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3, 52-week MOBILITY study (NCT01061736), sarilumab (150 or 200 mg subcutaneously every 2…
Abstract Number: 2480 • 2017 ACR/ARHP Annual Meeting
Improvements in Remission and Low Disease Activity Are Achieved with Ongoing Sarilumab Treatment, in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies
Mark C. Genovese¹, Erin K. Mangan², Jonathan Fay², Toshio Kimura², Hubert van Hoogstraten³ and Roy Fleischmann⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rɑ. Efficacy and safety of sarilumab (150 or 200 mg subcutaneously every 2 wks [q2w]) + conventional…
Abstract Number: 2867 • 2017 ACR/ARHP Annual Meeting
CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis
Vikas Gupta¹, Shobhita Katiyar², Ankita Singh², Ramnath Misra¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 30-40% of patients with RA do not respond to MTX, the first-line therapy in RA. Early identification of responders may allow the use…
Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting
Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate
Michael D. George¹, Brian Sauer², Chia-Chen Teng, MS², Grant Cannon², Bryant R. England³, Gail S. Kerr⁴, Ted R. Mikuls⁵ and Joshua Baker⁶, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴VAMC, Georgetown University, Washington, DC, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
Abstract Number: 443 • 2017 ACR/ARHP Annual Meeting
Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institute de Rheumatologie, Montreal, QC, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is recommended as part of initial therapy in early RA, but practices range widely. The objective of this analysis was to describe…
Abstract Number: 461 • 2017 ACR/ARHP Annual Meeting
Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University, Montreal, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁰University of Toronto, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Our objective was to compare RA treatment strategies with conventional and biologic DMARDs after an initial MTX strategy was ineffective or associated with a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].